CL2015000002A1 - Forma de administracion farmaceutica que comprende 5-cloro-n-({(5s)-2-oxo -3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida; procedimiento de preparacion y uso en la profilaxis y/o tratamiento de trastornos tromboembolicos. - Google Patents

Forma de administracion farmaceutica que comprende 5-cloro-n-({(5s)-2-oxo -3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida; procedimiento de preparacion y uso en la profilaxis y/o tratamiento de trastornos tromboembolicos.

Info

Publication number
CL2015000002A1
CL2015000002A1 CL2015000002A CL2015000002A CL2015000002A1 CL 2015000002 A1 CL2015000002 A1 CL 2015000002A1 CL 2015000002 A CL2015000002 A CL 2015000002A CL 2015000002 A CL2015000002 A CL 2015000002A CL 2015000002 A1 CL2015000002 A1 CL 2015000002A1
Authority
CL
Chile
Prior art keywords
oxo
thiophenecarboxamide
oxazolidin
morpholinyl
prophylaxis
Prior art date
Application number
CL2015000002A
Other languages
English (en)
Inventor
Klaus Benke
Heike Neumann
Wolfgang Mück
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48782297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000002(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2015000002A1 publication Critical patent/CL2015000002A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
CL2015000002A 2012-07-03 2015-01-02 Forma de administracion farmaceutica que comprende 5-cloro-n-({(5s)-2-oxo -3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida; procedimiento de preparacion y uso en la profilaxis y/o tratamiento de trastornos tromboembolicos. CL2015000002A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12174797 2012-07-03

Publications (1)

Publication Number Publication Date
CL2015000002A1 true CL2015000002A1 (es) 2015-05-29

Family

ID=48782297

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000002A CL2015000002A1 (es) 2012-07-03 2015-01-02 Forma de administracion farmaceutica que comprende 5-cloro-n-({(5s)-2-oxo -3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida; procedimiento de preparacion y uso en la profilaxis y/o tratamiento de trastornos tromboembolicos.

Country Status (33)

Country Link
US (2) US20140010876A1 (es)
EP (1) EP2869814B1 (es)
JP (1) JP6166781B2 (es)
KR (1) KR20150027284A (es)
CN (1) CN104582684A (es)
AP (1) AP3756A (es)
AR (1) AR091621A1 (es)
AU (1) AU2013286068A1 (es)
BR (1) BR112015000043A2 (es)
CA (1) CA2878123A1 (es)
CL (1) CL2015000002A1 (es)
CO (1) CO7240379A2 (es)
CR (1) CR20150001A (es)
CU (1) CU20140152A7 (es)
DO (1) DOP2015000001A (es)
EA (1) EA025016B1 (es)
EC (1) ECSP14033581A (es)
ES (1) ES2574627T3 (es)
GT (1) GT201400306A (es)
HK (1) HK1209635A1 (es)
IL (1) IL236455A0 (es)
IN (1) IN2014DN11066A (es)
MA (1) MA37721B1 (es)
MX (1) MX2015000053A (es)
NZ (1) NZ703733A (es)
PE (1) PE20150189A1 (es)
PH (1) PH12014502833A1 (es)
SG (1) SG11201408420YA (es)
TN (1) TN2014000541A1 (es)
TW (1) TW201414508A (es)
UY (1) UY34856A (es)
WO (1) WO2014005934A1 (es)
ZA (1) ZA201500759B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
HUE056739T2 (hu) * 2016-02-23 2022-03-28 Morgandane Scient Llc Páciensek kezelése rivaroxaban és verapamil együttes beadásával
CN107823166A (zh) * 2016-09-21 2018-03-23 齐鲁制药有限公司 一种利伐沙班片的制备方法
CA3107174A1 (en) * 2018-07-24 2020-01-30 Bayer Aktiengesellschaft Pharmaceutical dosage form which can be administered orally and has modified release
AU2019311234A1 (en) * 2018-07-24 2021-02-04 Bayer Aktiengesellschaft Pharmaceutical dosage form which can be administered orally and has modified release
US10722486B2 (en) 2018-08-13 2020-07-28 Morgandane Scientific, LLC Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
JP7465157B2 (ja) * 2020-06-15 2024-04-10 沢井製薬株式会社 リバーロキサバン含有口腔内崩壊錠の製造方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
JP2002516848A (ja) * 1998-06-03 2002-06-11 アルザ・コーポレーション 長時間の薬物療法を与える方法および装置
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
WO2010003641A1 (en) * 2008-07-08 2010-01-14 Ratiopharm Gmbh Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
RU2012155890A (ru) * 2010-06-22 2014-07-27 ТиДаблЮАй ФАРМАСЬЮТИКАЛЗ, ИНК. Композиции с контролируемым высвобождением с пониженным воздействием пищи

Also Published As

Publication number Publication date
EP2869814A1 (de) 2015-05-13
US20150125527A1 (en) 2015-05-07
AR091621A1 (es) 2015-02-18
TW201414508A (zh) 2014-04-16
AU2013286068A1 (en) 2015-01-29
MX2015000053A (es) 2015-04-10
MA37721B1 (fr) 2016-12-30
ECSP14033581A (es) 2015-12-31
PH12014502833A1 (en) 2015-02-02
SG11201408420YA (en) 2015-01-29
TN2014000541A1 (en) 2016-03-30
ES2574627T3 (es) 2016-06-21
CA2878123A1 (en) 2014-01-09
UY34856A (es) 2013-12-31
AP3756A (en) 2016-07-31
BR112015000043A2 (pt) 2017-06-27
NZ703733A (en) 2016-12-23
DOP2015000001A (es) 2015-07-15
EA201590142A1 (ru) 2015-06-30
CN104582684A (zh) 2015-04-29
AP2015008208A0 (en) 2015-01-31
JP6166781B2 (ja) 2017-07-19
IL236455A0 (en) 2015-02-26
CU20140152A7 (es) 2015-10-27
ZA201500759B (en) 2017-11-29
US20140010876A1 (en) 2014-01-09
EA025016B1 (ru) 2016-11-30
MA37721A1 (fr) 2016-05-31
KR20150027284A (ko) 2015-03-11
PE20150189A1 (es) 2015-01-31
EP2869814B1 (de) 2016-04-06
CR20150001A (es) 2015-02-06
CO7240379A2 (es) 2015-04-17
IN2014DN11066A (es) 2015-09-25
WO2014005934A1 (de) 2014-01-09
GT201400306A (es) 2015-08-25
JP2015521648A (ja) 2015-07-30
HK1209635A1 (en) 2016-04-08

Similar Documents

Publication Publication Date Title
CL2015000002A1 (es) Forma de administracion farmaceutica que comprende 5-cloro-n-({(5s)-2-oxo -3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida; procedimiento de preparacion y uso en la profilaxis y/o tratamiento de trastornos tromboembolicos.
ECSP088339A (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
ECSP066584A (es) Procedimiento para la producción de una composición farmacéutica sólida de administración oral
ECSP088341A (es) Nueva forma polimórfica y la forma amorfa de 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofenocarboxamida
HK1130252A1 (en) Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders
CL2014002048A1 (es) Compuestos derivados de 4-(benzoimidazol-2-il)-tiazol y derivados aza relacionados; composicion farmaceutica; y uso en la prevencion y el tratamiento de trastornos autoinmunes, inflamatorios, enfermedades infecciosas, entre otras.
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX370061B (es) Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales.
IN2012MU03359A (es)
WO2012080184A3 (de) Flüssige, oral applizierbare pharmazeutische zusammensetzungen enthaltend 5-chlor-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
BR112016024825A2 (pt) composição contendo rivaroxaban e processo para fabricação de uma composição compreendendo rivaroxaban
SG11201700066TA (en) Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same